• Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer
• Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet need
• Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage bio